Explore our brands

Our brands bring together the industry's most influential leaders and scientific experts, inspiring thought-provoking and insightful content that offers a unique perspective on R&D trends and challenges.
Contact
Immunotherapy (Non-Oncology) | Webinars

Uncovering Mechanisms of Immunotherapy Response & Resistance with Single Cell & Spatial Multiomics

22 February 2024
Discover how 10x Genomics' spatial technologies are revolutionising the study of immunotherapies in solid tumors
Watch the full webinar

In this webinar, Abbey Cucthin, Associate Director, Oncology Marketing, discusses how:

  • Visium spatial gene expression uncovers cellular organization within tissue, combining whole transcriptome and targeted protein co-detection with morphological context
  • Xenium in Situ provides subcellular resolution for the characterization of 100s to 1000s of RNAs and multiplexed protein analysis
  • To analyze the role of tertiary lymphoid structures in generating localized anti-tumor immune responses and their association with checkpoint blockade response using spatial technologies
Watch the full webinar

Speaker Biographies

Abbey Cutchin, Associate Director, Oncology Marketing, 10x Genomics

As the oncology marketing lead at 10x Genomics, Abbey Cutchin focuses on developing evidence for using single-cell and spatial multiomics in emerging basic and translational cancer research applications. Previously, Abbey was on the Global Market Development team at Illumina and received her degree in Bioengineering from Stanford.

Related Resources

Advancing Immunotherapy: The Critical Role of GMP-Grade Cytokines in Cell Therapy

On-demand webinar presented by Ritwika Biswas, Field Application Scientist at Sino Biological
Read More

University College London Hospitals Begins Clinical Trial for One-Off CAR T Treatment for Lupus

The possibility of a one-off treatment for lupus could offer hope to 69,000 patients in the UK.
Read More

Clesrovimab Shows Positive Results as Preventative Treatment for RSV in Pre-Term and Full-Term Infants

The phase IIb/III met both its primary and secondary endpoints in infants one year old or younger.
Read More